These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 12495285

  • 1. Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure.
    Vigneau C, Ardiet C, Bret M, Laville M, Fiere D, Tranchand B, Fouque D.
    J Nephrol; 2002; 15(6):684-9. PubMed ID: 12495285
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
    Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C, Dib M, Guillerm G, Salles B, Eschard JP, Lenain P, Casassus P, Azaïs I, Decaux O, Garderet L, Mathiot C, Fontan J, Lafon I, Virion JM, Moreau P.
    J Clin Oncol; 2009 Aug 01; 27(22):3664-70. PubMed ID: 19451428
    [Abstract] [Full Text] [Related]

  • 3. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study.
    Tricot G, Alberts DS, Johnson C, Roe DJ, Dorr RT, Bracy D, Vesole DH, Jagannath S, Meyers R, Barlogie B.
    Clin Cancer Res; 1996 Jun 01; 2(6):947-52. PubMed ID: 9816255
    [Abstract] [Full Text] [Related]

  • 4. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
    Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, Orlowski RZ, Richardson PG, Anderson J, Nix D, Esseltine DL, Anderson KC, SUMMIT/CREST Investigators.
    Cancer; 2005 Mar 15; 103(6):1195-200. PubMed ID: 15690325
    [Abstract] [Full Text] [Related]

  • 5. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
    Dimopoulos MA, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kastritis E, Kropff M, Petrucci MT, Delforge M, Alexeeva J, Schots R, Masszi T, Mateos MV, Deraedt W, Liu K, Cakana A, van de Velde H, San Miguel JF.
    J Clin Oncol; 2009 Dec 20; 27(36):6086-93. PubMed ID: 19858394
    [Abstract] [Full Text] [Related]

  • 6. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
    Berenson JR, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R, Purner M, Lee SP, Wilson J, Morrison B, Adams J, Schenkein D, Swift R.
    J Clin Oncol; 2006 Feb 20; 24(6):937-44. PubMed ID: 16418495
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure--a retrospective analysis and recommendations for dose adjustment.
    Carlson K, Hjorth M, Knudsen LM, Nordic Myeloma Study Group.
    Br J Haematol; 2005 Mar 20; 128(5):631-5. PubMed ID: 15725084
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
    Palumbo A, Avonto I, Bruno B, Ambrosini MT, Bringhen S, Cavallo F, Falco P, Boccadoro M.
    Eur J Haematol; 2006 Apr 20; 76(4):273-7. PubMed ID: 16519697
    [Abstract] [Full Text] [Related]

  • 12. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
    Grazziutti ML, Dong L, Miceli MH, Krishna SG, Kiwan E, Syed N, Fassas A, van Rhee F, Klaus H, Barlogie B, Anaissie EJ.
    Bone Marrow Transplant; 2006 Oct 20; 38(7):501-6. PubMed ID: 16980998
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma.
    García-Sanz R, Hernández JM, Sureda A, García-Laraña J, Prósper F, Alegre A, Bárez A, Mateos MV, San Miguel JF.
    Hematol Oncol; 2006 Dec 20; 24(4):205-11. PubMed ID: 17006969
    [Abstract] [Full Text] [Related]

  • 15. Melphalan and dexamethasone for patients with multiple myeloma who are not candidates for autologous stem cell transplantation.
    Sharma A, Lokeshwar N, Raina V, Mohanti BK, Kumar R.
    Natl Med J India; 2007 Dec 20; 20(3):121-4. PubMed ID: 17867615
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
    Brinker BT, Waller EK, Leong T, Heffner LT, Redei I, Langston AA, Lonial S.
    Cancer; 2006 May 15; 106(10):2171-80. PubMed ID: 16598756
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.